Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy
Authors:
- 11 September 2015
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 19 (3) , 894-901
Abstract
Background Watering eyes is a common late adverse event associated with S-1 chemotherapy; however, the frequency and predictive factors are not known. Methods This study included 304 consecutive gastric cancer patients treated with adjuvant S-1 monotherapy for 1 year at Shizuoka Cancer Center. We retrospectively evaluated the frequency of watering eyes, and explored other nonhematological adverse events during the first course of S-1 monotherapy which could become predictive factors for watering eyes. Results The severest grade of watering eyes during S-1 monotherapy was grade 2 in 41 patients (13.5 %) and grade 3 in 36 patients (11.8 %). The median time to onset of grade 2 and grade 3 watering eyes was 82 days (range 6–344 days) and 249 days (range 84–653 days), respectively, and the median cumulative S-1 dose at the onset of grade 2 and grade 3 watering eyes was 4174 mg/m2 (range 491–16,095 mg/m2) and 10,243 mg/m2 (range 4943–16,341 mg/m2), respectively. Multivariate analysis showed that anorexia (odds ratio 2.37, P = 0.008), oral mucositis (odds ratio 3.86, P = 0.0003), skin hyperpigmentation (odds ratio 3.84, P = 0.0001), and rash (odds ratio 3.76, P = 0.01) observed during the first course were significantly associated with watering eyes. Conclusion The risk of watering eyes was higher in patients who also had anorexia, oral mucositis, skin hyperpigmentation, or rash during first course of S-1 monotherapy than in those without them.Keywords
This publication has 14 references indexed in Scilit:
- Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapyAnnals of Oncology, 2012
- Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drugJapanese Journal of Ophthalmology, 2012
- Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)Gastric Cancer, 2011
- [Investigation of epiphora following S-1 therapy].2011
- Two Cases of Lacrimal Drainage Obstruction Associated With S-1 Anticancer TreatmentJournal of the Korean Ophthalmological Society, 2010
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 studyThe Lancet Oncology, 2009
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Canalicular and Nasolacrimal Duct Blockage: An Ocular Side Effect Associated With the Antineoplastic Drug S-1American Journal of Ophthalmology, 2005
- Lacrimal canalicular stenosis associated with systemic 5‐fluorouracil therapyActa Ophthalmologica Scandinavica, 2000